Cargando…

Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave

BACKGROUND: We aimed to detect SARS-CoV-2 serum antibodies in the general population of the Netherlands and identify risk factors for seropositivity amidst the first COVID-19 epidemic wave. METHODS: Participants (n=3207, aged 2–90 years), enrolled from a previously established nationwide serosurveil...

Descripción completa

Detalles Bibliográficos
Autores principales: Vos, Eric R A, den Hartog, Gerco, Schepp, Rutger M, Kaaijk, Patricia, van Vliet, Jeffrey, Helm, Kina, Smits, Gaby, Wijmenga-Monsuur, Alienke, Verberk, Janneke D M, van Boven, Michiel, van Binnendijk, Rob S, de Melker, Hester E, Mollema, Liesbeth, van der Klis, Fiona R M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142429/
https://www.ncbi.nlm.nih.gov/pubmed/33249407
http://dx.doi.org/10.1136/jech-2020-215678
_version_ 1783696549247713280
author Vos, Eric R A
den Hartog, Gerco
Schepp, Rutger M
Kaaijk, Patricia
van Vliet, Jeffrey
Helm, Kina
Smits, Gaby
Wijmenga-Monsuur, Alienke
Verberk, Janneke D M
van Boven, Michiel
van Binnendijk, Rob S
de Melker, Hester E
Mollema, Liesbeth
van der Klis, Fiona R M
author_facet Vos, Eric R A
den Hartog, Gerco
Schepp, Rutger M
Kaaijk, Patricia
van Vliet, Jeffrey
Helm, Kina
Smits, Gaby
Wijmenga-Monsuur, Alienke
Verberk, Janneke D M
van Boven, Michiel
van Binnendijk, Rob S
de Melker, Hester E
Mollema, Liesbeth
van der Klis, Fiona R M
author_sort Vos, Eric R A
collection PubMed
description BACKGROUND: We aimed to detect SARS-CoV-2 serum antibodies in the general population of the Netherlands and identify risk factors for seropositivity amidst the first COVID-19 epidemic wave. METHODS: Participants (n=3207, aged 2–90 years), enrolled from a previously established nationwide serosurveillance study, provided a self-collected fingerstick blood sample and completed a questionnaire (median inclusion date 3 April 2020). IgG antibodies targeted against the spike S1-protein of SARS-CoV-2 were quantified using a validated multiplex-immunoassay. Seroprevalence was estimated controlling for survey design, individual pre-pandemic concentration, and test performance. Random-effects logistic regression identified risk factors for seropositivity. RESULTS: Overall seroprevalence in the Netherlands was 2.8% (95% CI 2.1 to 3.7), with no differences between sexes or ethnic background, and regionally ranging between 1.3 and 4.0%. Estimates were highest among 18–39 year-olds (4.9%), and lowest in children 2–17 years (1.7%). Multivariable analysis revealed that persons taking immunosuppressants and those from the Orthodox-Reformed Protestant community had over four times higher odds of being seropositive compared to others. Anosmia/ageusia was the most discriminative symptom between seropositive (53%) and seronegative persons (4%, p<0.0001). Antibody concentrations in seropositive persons were significantly higher in those with fever or dyspnoea in contrast to those without (p=0.01 and p=0.04, respectively). CONCLUSIONS: In the midst of the first epidemic wave, 2.8% of the Dutch population was estimated to be infected with SARS-CoV-2, that is, 30 times higher than reported. This study identified independent groups with increased odds for seropositivity that may require specific surveillance measures to guide future protective interventions internationally, including vaccination once available.
format Online
Article
Text
id pubmed-8142429
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-81424292021-06-07 Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave Vos, Eric R A den Hartog, Gerco Schepp, Rutger M Kaaijk, Patricia van Vliet, Jeffrey Helm, Kina Smits, Gaby Wijmenga-Monsuur, Alienke Verberk, Janneke D M van Boven, Michiel van Binnendijk, Rob S de Melker, Hester E Mollema, Liesbeth van der Klis, Fiona R M J Epidemiol Community Health Original Research BACKGROUND: We aimed to detect SARS-CoV-2 serum antibodies in the general population of the Netherlands and identify risk factors for seropositivity amidst the first COVID-19 epidemic wave. METHODS: Participants (n=3207, aged 2–90 years), enrolled from a previously established nationwide serosurveillance study, provided a self-collected fingerstick blood sample and completed a questionnaire (median inclusion date 3 April 2020). IgG antibodies targeted against the spike S1-protein of SARS-CoV-2 were quantified using a validated multiplex-immunoassay. Seroprevalence was estimated controlling for survey design, individual pre-pandemic concentration, and test performance. Random-effects logistic regression identified risk factors for seropositivity. RESULTS: Overall seroprevalence in the Netherlands was 2.8% (95% CI 2.1 to 3.7), with no differences between sexes or ethnic background, and regionally ranging between 1.3 and 4.0%. Estimates were highest among 18–39 year-olds (4.9%), and lowest in children 2–17 years (1.7%). Multivariable analysis revealed that persons taking immunosuppressants and those from the Orthodox-Reformed Protestant community had over four times higher odds of being seropositive compared to others. Anosmia/ageusia was the most discriminative symptom between seropositive (53%) and seronegative persons (4%, p<0.0001). Antibody concentrations in seropositive persons were significantly higher in those with fever or dyspnoea in contrast to those without (p=0.01 and p=0.04, respectively). CONCLUSIONS: In the midst of the first epidemic wave, 2.8% of the Dutch population was estimated to be infected with SARS-CoV-2, that is, 30 times higher than reported. This study identified independent groups with increased odds for seropositivity that may require specific surveillance measures to guide future protective interventions internationally, including vaccination once available. BMJ Publishing Group 2021-06 2020-11-30 /pmc/articles/PMC8142429/ /pubmed/33249407 http://dx.doi.org/10.1136/jech-2020-215678 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Vos, Eric R A
den Hartog, Gerco
Schepp, Rutger M
Kaaijk, Patricia
van Vliet, Jeffrey
Helm, Kina
Smits, Gaby
Wijmenga-Monsuur, Alienke
Verberk, Janneke D M
van Boven, Michiel
van Binnendijk, Rob S
de Melker, Hester E
Mollema, Liesbeth
van der Klis, Fiona R M
Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave
title Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave
title_full Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave
title_fullStr Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave
title_full_unstemmed Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave
title_short Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave
title_sort nationwide seroprevalence of sars-cov-2 and identification of risk factors in the general population of the netherlands during the first epidemic wave
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142429/
https://www.ncbi.nlm.nih.gov/pubmed/33249407
http://dx.doi.org/10.1136/jech-2020-215678
work_keys_str_mv AT vosericra nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT denhartoggerco nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT schepprutgerm nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT kaaijkpatricia nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT vanvlietjeffrey nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT helmkina nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT smitsgaby nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT wijmengamonsuuralienke nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT verberkjannekedm nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT vanbovenmichiel nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT vanbinnendijkrobs nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT demelkerhestere nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT mollemaliesbeth nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave
AT vanderklisfionarm nationwideseroprevalenceofsarscov2andidentificationofriskfactorsinthegeneralpopulationofthenetherlandsduringthefirstepidemicwave